ID

11997

Description

Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.; ODM derived from: https://clinicaltrials.gov/show/NCT02470065 Principal Investigator: Sanjay Popat, PhD Royal Marsden NHS Foundation Trust

Link

https://clinicaltrials.gov/show/NCT02470065

Keywords

Versions (1)
  1. 8/31/15 8/31/15 -
Uploaded on

August 31, 2015

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Non Small Cell Lung Cancer NCT02470065

English

Eligibility Non Small Cell Lung Cancer NCT02470065

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI-1
C1512693
histological or cytological diagnosis of nsclc;
Description

diagnosis; NSCLC

Data type

boolean

Alias
UMLS CUI [1]
C0011900
UMLS CUI [2]
C0007131
Patients considered operable and with resectable tumor with curative intent (anatomical resection and systematic lymph node dissection) based on evaluation by a thoracic multi-disciplinary team composed of at least a thoracic surgeon, oncologist and radiologist;
Description

Patients considered operable and with resectable tumor with curative intent (anatomical resection and systematic lymph node dissection) based on evaluation by a thoracic multi-disciplinary team composed of at least a thoracic surgeon, oncologist and radiologist;

Data type

boolean

Alias
UMLS CUI [1]
C1273390
UMLS CUI [2]
C0027651
Stage I-III (T1a-3, N0-1, M0 according to UICC version 7) NSCLC by local staging criteria potentially treatable by radical (curative) surgery. Patients with T1 tumor at baseline will be limited to 20%;
Description

Stage I-III (T1a-3, N0-1, M0 according to UICC version 7) NSCLC by local staging criteria potentially treatable by radical (curative) surgery. Patients with T1 tumor at baseline will be limited to 20%;

Data type

boolean

Alias
UMLS CUI [1]
C0178759
Radiologically measurable disease according to RECIST criteria 1.1; assessed by chest and upper abdomen CT scan within 2 weeks (+1 week) prior to registration); brain CT scan or MRI according to local practice
Description

Radiologically measurable disease according to RECIST criteria 1.1; assessed by chest and upper abdomen CT scan within 2 weeks (+1 week) prior to registration); brain CT scan or MRI according to local practice

Data type

boolean

Alias
UMLS CUI [1]
C1513041
No prior treatment for NSCLC is allowed
Description

prior treatment

Data type

boolean

Alias
UMLS CUI [1]
C1514463
Adequate tissue in terms of quality and quantity for EGFR local testing.
Description

Adequate tissue in terms of quality and quantity for EGFR local testing.

Data type

boolean

Alias
UMLS CUI [1]
C0034802
UMLS CUI [2]
C0022885
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI-1
C0680251
no adequate bone marrow function within 2 weeks prior to randomization
Description

no adequate bone marrow function within 2 weeks prior to randomization

Data type

boolean

Alias
UMLS CUI [1]
C1389329
no adequate liver function. Patients with Gilbert's syndrome total bilirubin must be below 4 times institutional upper limit of normal; within 2 weeks prior to randomization
Description

no adequate liver function. Patients with Gilbert's syndrome total bilirubin must be below 4 times institutional upper limit of normal; within 2 weeks prior to randomization

Data type

boolean

Alias
UMLS CUI [1]
C0232741
no adequate renal function within 2 weeks prior to randomization
Description

no adequate renal function within 2 weeks prior to randomization

Data type

boolean

Alias
UMLS CUI [1]
C0232804
known positivity to human immunodeficiency virus (hiv), hepatitis b or hepatitis c
Description

known positivity to human immunodeficiency virus (HIV), hepatitis B or hepatitis C

Data type

boolean

Alias
UMLS CUI [1]
C0019699
UMLS CUI [2]
C0019158
known history of allergic reactions attributed to compounds of similar chemical or biological composition;
Description

known history of allergic reactions attributed to compounds of similar chemical or biological composition

Data type

boolean

Alias
UMLS CUI [1]
C1527304
history of a hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years, except pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non melanoma skin cancer or carcinoma in situ of the cervix;
Description

history of a hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years, except pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non melanoma skin cancer or carcinoma in situ of the cervix;

Data type

boolean

Alias
UMLS CUI [1]
C0006826
Back to the top of the page

Similar models

Eligibility Non Small Cell Lung Cancer NCT02470065

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Inclusion Criteria
C1512693 (UMLS CUI-1)
diagnosis; NSCLC
Item
histological or cytological diagnosis of nsclc;
boolean
C0011900 (UMLS CUI [1])
C0007131 (UMLS CUI [2])
curative treatment; Neoplasms
Item
Patients considered operable and with resectable tumor with curative intent (anatomical resection and systematic lymph node dissection) based on evaluation by a thoracic multi-disciplinary team composed of at least a thoracic surgeon, oncologist and radiologist;
boolean
C1273390 (UMLS CUI [1])
C0027651 (UMLS CUI [2])
Tumor Stage Classification
Item
Stage I-III (T1a-3, N0-1, M0 according to UICC version 7) NSCLC by local staging criteria potentially treatable by radical (curative) surgery. Patients with T1 tumor at baseline will be limited to 20%;
boolean
C0178759 (UMLS CUI [1])
measurable disease
Item
Radiologically measurable disease according to RECIST criteria 1.1; assessed by chest and upper abdomen CT scan within 2 weeks (+1 week) prior to registration); brain CT scan or MRI according to local practice
boolean
C1513041 (UMLS CUI [1])
prior treatment
Item
No prior treatment for NSCLC is allowed
boolean
C1514463 (UMLS CUI [1])
Epidermal Growth Factor Receptor; test
Item
Adequate tissue in terms of quality and quantity for EGFR local testing.
boolean
C0034802 (UMLS CUI [1])
C0022885 (UMLS CUI [2])
Item Group
Exclusion Criteria
C0680251 (UMLS CUI-1)
poor function; bone marrow
Item
no adequate bone marrow function within 2 weeks prior to randomization
boolean
C1389329 (UMLS CUI [1])
liver function
Item
no adequate liver function. Patients with Gilbert's syndrome total bilirubin must be below 4 times institutional upper limit of normal; within 2 weeks prior to randomization
boolean
C0232741 (UMLS CUI [1])
renal function
Item
no adequate renal function within 2 weeks prior to randomization
boolean
C0232804 (UMLS CUI [1])
HIV positive; Hepatitis
Item
known positivity to human immunodeficiency virus (hiv), hepatitis b or hepatitis c
boolean
C0019699 (UMLS CUI [1])
C0019158 (UMLS CUI [2])
allergic reaction
Item
known history of allergic reactions attributed to compounds of similar chemical or biological composition;
boolean
C1527304 (UMLS CUI [1])
Malignant Neoplasms
Item
history of a hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 years, except pT1-2 prostatic cancer Gleason score < 6, superficial bladder cancer, non melanoma skin cancer or carcinoma in situ of the cervix;
boolean
C0006826 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial